ABBV-400 Shows Early Promise in Pretreated, Metastatic Colorectal Cancer
“It does appear like MET expression could be one of the mechanisms wherein you could differentiate between responders and non-responders,” Kanwal P.S. Raghav, MBBS, MD, stated.
Extended Follow-Up May Elucidate How ctDNA Impacts RMC-6236 PDAC Outcomes
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
“Frozen section is destructive. It ruins the tissue, it consumes the tissue, and it affects downstream molecular analysis,” according to Farzad Fereidouni, PhD.
Top 5 Takeaways for Gastrointestinal Cancer Management From 2025 ASCO GI
Data from 2025 ASCO GI support the potential role that combinations such as nivolumab/ipilimumab may play a part in managing different types of GI cancers.
Atezolizumab and Tremelimumab Combos Yield No Survival Difference in First-Line HCC
Atezolizumab and bevacizumab yielded a median OS of 14.0 months vs 14.6 months with tremelimumab followed by durvalumab, a retrospective cohort study found.
Tucatinib Combo Shows Meaningful Activity in HER2+ Metastatic Breast Cancer
Tucatinib plus trastuzumab was well tolerated in patients with metastatic breast cancer and consistent with the combination’s established safety profile.
First-Line Serplulimab Plus HLX04 Shows Manageable Safety in Advanced HCC
Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.
Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
Anant Madabhushi, PhD, stated that MarginCall, a surgery tool he is developing can improve patient outcomes in breast and ovarian cancer surgeries.
Zipalertinib Meets Primary ORR End Point in EGFR exon 20 NSCLC
Full results from the phase 1/2 REZILIENT1 trial evaluating zipalertinib in NSCLC will be shared at a future medical conference.
TRAQinform IQ: Individual Lesion Change to Understand Disease Heterogeneity
TRAQinform IQ provides spatial and temporal information for each lesion from serial PET/CT scans, helping to inform the next steps for cancer treatment.
Investigational Agent Improves PFS Vs Everolimus in Grade 1/2 GI NETs
Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.
Belantamab Mafodotin Shows Real-World Efficacy in Pretreated R/R Myeloma
Having extramedullary disease correlated with worse PFS and OS among patients who received belantamab mafodotin for relapsed/refractory multiple myeloma.
Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
The FIBI technology, created by Farzad Fereidouni, PhD, when combined with AI eliminates the need for frozen sections and other labor-intensive oncology surgery practices.
Inavolisib Combo Meets OS End Point in PIK3CA+ Metastatic Breast Cancer
The phase 3 INAVO120 trial reported statistically significant OS results in patients with PIK3CA-mutant, locally advanced or metastatic breast cancer.
T-DM1 Shows Promise in HER2+ Biliary Tract Cancer
A phase 2 trial found T-DM1 to be a tolerable treatment option for patients with HER2-positive biliary tract adenocarcinoma.
Encorafenib Combo Shows Universal Activity in CRC Prognostic Groups
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
Data Monitoring Committee OKs INVINCIBLE-3 Sarcoma Trial Continuation
The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.
T-DXd Benefit May Extend to Earlier Settings and HER2-Low Breast Cancers
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
CD19-directed CAR T therapy for T-cell/histiocyte-rich large B-cell lymphoma
Researchers from the University of Wisconsin, Cornell, and a consortium of other institutions conducted a retrospective analysis on CD19-directed CAR T-cell therapy for R/R T-cell/histiocyte-rich LBCL.
Inflammation-induced epigenetic imprinting regulates intestinal stem cells
Researchers from Bambino Gesù Children’s Hospital and Sapienza University in Rome, Italy examined the recovery and function of MAIT cells in pediatric and young adult patients following allo-HSCT.
Enhanced Postoperative Recovery May Improve Outcomes in Elderly NSCLC
Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.
FDA Approves T-DXd in HER2-Low/Ultralow Breast Cancer
Results from the DESTINY-Breast06 trial led to the approval of T-DXd for patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer.
Belzutifan Receives Priority Review in Pheochromocytoma/Paraganglioma
Data from the phase 2 LITESPARK-015 trial support the sNDA for belzutifan in patients with pheochromocytoma or paraganglioma.
Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.
Positive Responses Demonstrated by Adagrasib and Cetuximab in KRAS G12C-Mutant mCRC
At a longer follow-up, adagrasib with cetuximab maintained meaningful efficacy and elicited an ORR of 34%, results from the phase 1/2 KRYSTAL-1 showed.
Fast Track Designation Given to Novel PET Imaging Agent in Prostate Cancer
The imaging agent led to changes in intended treatment plans for 48% of patients with prostate cancer and biochemical recurrence after definitive therapy.
Fruquintinib Combo Shows Activity in Pretreated Metastatic CRC
Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.
Pembrolizumab Combo Does Not Meet OS End Point in Advanced Gastric Cancer
Pembrolizumab plus lenvatinib showed a safety profile consistent with previous reports evaluating the combination.
Ramucirumab/Somatostatin Displays Prolonged Survival in Advanced NET
A phase 2 trial revealed survival with ramucirumab plus somatostatin was consistent with other VEGF pathways in treating advanced neuroendocrine tumors.
Palliative Care Consultations Correlate With Improved QOL in Esophageal Cancer
Patients with esophageal cancer who received palliative care consultations during end-of-life treatment experienced a decreased financial burden compared with patients who did not.
